Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.

Pankuch GA, Hoellman D, Bryskier A, Lowther J, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Nov;50(11):3914-6.

2.
3.

Anti-MRSA agents: under investigation, in the exploratory phase and clinically available.

Bryskier A.

Expert Rev Anti Infect Ther. 2005 Aug;3(4):505-53. Review.

PMID:
16107196
4.

New research in macrolides and ketolides since 1997.

Bryskier A.

Expert Opin Investig Drugs. 1999 Aug;8(8):1171-94.

PMID:
15992143
5.

Novelties in the field of fluoroquinolones.

Bryskier A.

Expert Opin Investig Drugs. 1997 Sep;6(9):1227-45.

PMID:
15991898
6.

Novelties in the field of macrolides.

Bryskier A.

Expert Opin Investig Drugs. 1997 Nov;6(11):1697-709.

PMID:
15989574
7.

Dual beta-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment.

Bryskier A.

Expert Opin Investig Drugs. 1997 Oct;6(10):1479-99.

PMID:
15989514
8.

Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.

Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, Rangaraju M, Drusano GL.

Diagn Microbiol Infect Dis. 2005 May;52(1):45-52.

PMID:
15878442
9.

In vitro evaluation of faropenem activity against anaerobic bacteria.

Behra-Miellet J, Dubreuil L, Bryskier A.

J Chemother. 2005 Feb;17(1):36-45.

PMID:
15828442
10.

Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey.

Sener B, Köseoglu O, Gür D, Bryskier A.

J Chemother. 2005 Feb;17(1):31-5.

PMID:
15828441
12.

The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli.

Chollet R, Chevalier J, Bryskier A, Pagès JM.

Antimicrob Agents Chemother. 2004 Sep;48(9):3621-4.

13.

Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice.

Törmäkangas L, Saario E, Bem David D, Bryskier A, Leinonen M, Saikku P.

J Antimicrob Chemother. 2004 Jun;53(6):1101-4. Epub 2004 Apr 29.

PMID:
15117927
14.

Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany.

Reinert RR, Lütticken R, Sutcliffe JA, Tait-Kamradt A, Cil MY, Schorn HM, Bryskier A, Al-Lahham A.

Antimicrob Agents Chemother. 2004 Apr;48(4):1369-73.

15.

Comparison of the in vitro efficacy of telithromycin (HMR 3647) and levofloxacin with 22 antibiotic compounds against Bosea and Afipia species.

La Scola B, Bryskier A, Raoult D.

J Antimicrob Chemother. 2004 Apr;53(4):683-5. Epub 2004 Mar 3. No abstract available.

PMID:
14998981
16.

Preparation of stock solutions of macrolide and ketolide compounds for antimicrobial susceptibility tests.

Barry A, Bryskier A, Traczewski M, Brown S.

Clin Microbiol Infect. 2004 Jan;10(1):78-83.

17.

Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Pankuch GA, Kelly LM, Lin G, Bryskier A, Couturier C, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Oct;47(10):3270-4.

18.

In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Bemer P, Juvin ME, Bryskier A, Drugeon H.

Antimicrob Agents Chemother. 2003 Sep;47(9):3025-9.

19.

[Roxitromycin: Review of Its Antimicrobial Activity]

Bryskier A.

Russ J Immunol. 1998 Jul;3(2):210-220. Russian. No abstract available.

PMID:
12687099
20.

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Apr;47(4):1187-92.

21.

Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.

Reinert RR, Lütticken R, Bryskier A, Al-Lahham A.

Antimicrob Agents Chemother. 2003 Feb;47(2):489-93.

22.

Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae.

Bozdogan B, Clark C, Bryskier A, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Jan;47(1):405-7.

23.

Bacillus anthracis and antibacterial agents.

Bryskier A.

Clin Microbiol Infect. 2002 Aug;8(8):467-78. Review.

24.

Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Maurin M, Bryskier A, Raoult D.

Antimicrob Agents Chemother. 2002 Sep;46(9):3065-7.

25.
26.

The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens.

Goldstein F, Bryskier A, Appelbaum PC, Bauernfeind A, Jacobs M, Schito GC, Wise R.

Clin Microbiol Infect. 1998 Apr;4 Suppl 2:S8-S18. No abstract available.

27.

Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens.

Marchese A, Debbia EA, Bryskier A, Schito GC.

Clin Microbiol Infect. 1999 May;5(5):282-287. No abstract available.

28.

Fluoroquinolones and tuberculosis.

Bryskier A, Lowther J.

Expert Opin Investig Drugs. 2002 Feb;11(2):233-58. Review.

PMID:
11829714
29.

Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin.

Lascols C, Bryskier A, Soussy CJ, Tanković J.

J Antimicrob Chemother. 2001 Nov;48(5):738-40. No abstract available.

PMID:
11679568
31.

Perfecting the ring and extending the antibacterial spectrum: 'the multiple generations'.

Bryskier A.

Clin Microbiol Infect. 2000;6 Suppl 3:13-21. Review. No abstract available.

32.

Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany.

Brandt CM, Honscha M, Truong ND, Holland R, Hövener B, Bryskier A, Lütticken R, Reinert RR.

Microb Drug Resist. 2001 Summer;7(2):165-70.

PMID:
11442342
33.

Classification of oral cephalosporins. A matter for debate.

Williams JD, Naber KG, Bryskier A, Høby N, Gould IM, Periti P, Giamarellou H, Rouveix B.

Int J Antimicrob Agents. 2001 Jun;17(6):443-50.

PMID:
11397613
34.

Telithromycin--an innovative ketolide antimicrobials.

Bryskier A.

Jpn J Antibiot. 2001 Feb;54 Suppl A:64-9. Review. No abstract available.

PMID:
11296411
35.

Ketolides-telithromycin, an example of a new class of antibacterial agents.

Bryskier A.

Clin Microbiol Infect. 2000 Dec;6(12):661-9. Review.

36.

The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistance.

Fernández-Roblas R, Calvo R, Esteban J, Bryskier A, Soriano F.

J Antimicrob Chemother. 1999 Feb;43(2):285-9.

PMID:
11252337
37.

The suppository form of antibiotic administration: pharmacokinetics and clinical application.

Bergogne-Bérézin E, Bryskier A.

J Antimicrob Chemother. 1999 Feb;43(2):177-85. Review.

PMID:
11252322
38.

Anti-anaerobic activity of antibacterial agents.

Bryskier A.

Expert Opin Investig Drugs. 2001 Feb;10(2):239-67. Review.

PMID:
11178339
39.

Cephems: fifty years of continuous research.

Bryskier A.

J Antibiot (Tokyo). 2000 Oct;53(10):1028-37.

40.

Novelties in the field of anti-infective compounds in 1999.

Bryskier A.

Clin Infect Dis. 2000 Dec;31(6):1423-66. Epub 2000 Nov 29. Review.

PMID:
11096013
41.

In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.

Joly-Guillou ML, Wolff M, Farinotti R, Bryskier A, Carbon C.

J Antimicrob Chemother. 2000 Nov;46(5):827-30.

PMID:
11062208
42.

In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.

Bemer-Melchior P, Juvin ME, Tassin S, Bryskier A, Schito GC, Drugeon HB.

Antimicrob Agents Chemother. 2000 Nov;44(11):2999-3002.

43.

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.

Bemer-Melchior P, Bryskier A, Drugeon HB.

J Antimicrob Chemother. 2000 Oct;46(4):571-6.

PMID:
11020254
45.
46.

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Bebear CM, Renaudin H, Bryskier A, Bebear C.

Antimicrob Agents Chemother. 2000 Jul;44(7):1980-2.

48.
49.

Novelties in the field of anti-infectives in 1998.

Bryskier A.

Clin Infect Dis. 1999 Sep;29(3):632-58. Review.

PMID:
10530460

Supplemental Content

Loading ...
Support Center